Results 121 to 130 of about 99,677 (264)
Rheumatoid arthritis and spondyloarthropathy [PDF]
, 2013 Part 2 of the article can be found through this link:
https://www.um.edu.mt/library/oar//handle/123456789/13280Rheumatoid arthritis (RA) and
spondyloarthropathy are two
groups of inflammatory joint disease.Vassallo, Pierrecore Predicting epilepsy after new onset refractory status epilepticus due to autoimmune encephalitis: The DAME score
Epilepsia, EarlyView.Abstract Objective
This study aimed to identify risk factors and develop a predictive scoring system for autoimmune‐associated epilepsy in subjects with autoimmune encephalitis presenting with new onset refractory status epilepticus (NORSE). Methods
This retrospective, multicenter, cohort study included subjects who presented with NORSE at the onset of Simona Lattanzi, Sara Matricardi, Alberto Vogrig, Giada Pauletto, Margherita Nosadini, Stefano Sartori, Federico Massa, Luana Benedetti, Stefano Meletti, Francesca Bisulli, Elena Freri, Francesca Felicia Operto, Silvia Bozzetti, Sara Mariotto, Simone Beretta, Eleonora Rosati, Elisabetta Cesaroni, Carla Marini, Tiziana Granata, Flavio Villani, Immune Epilepsies Study Group of the Italian League Against Epilepsy, Ruggero Bernabei, Stefania Maria Bova, Silva Cappanera, Luigi Caputi, Edward Cesnik, Francesco Deleo, Lidia Di Vito, Giuseppe D’Orsi, Giovanni Falcicchio, Elisa Fallica, Edoardo Ferlazzo, Lucia Fusco, Matteo Gastaldi, Giada Giovannini, Angela La Neve, Claudio Liguori, Pietro Mattioli, Lorenzo Muccioli, Carlotta Mutti, Angelo Pascarella, Elena Pasini, Daniela Passarelli, Francesca Ragona, Romana Rizzi, Elena Tartara, Valentina Tontini, Alberto Verrotti, Federica Zibordi, Lucia Zinno, Antonio Zito +50 morewiley +1 more sourceExploring pathways leading to drug‐resistant epilepsy for patients with cryptogenic new onset refractory status epilepticus
Epilepsia, EarlyView.Abstract Objective
Cryptogenic new onset refractory status epilepticus (cNORSE) carries high risks of long‐term disability and post‐NORSE epilepsy, but mechanisms remain unclear. We aimed to assess the predictive value of inflammatory and brain injury biomarkers and determine whether immune disturbances persist in the chronic phase. Methods
We enrolled Aurélie Hanin, Clémence Marois, Martin Guillemaud, Mario Chavez, Léa Cosme, Zineb Hayatou, Aurore Besnard, Gwen Goudard, Véronique Masson, Louis Cousyn, Margaux Cheval, Jérôme A. Denis, Rana Alkouri, Foudil Lamari, Francesca Bisulli, Krista Eschbach, Raquel Farias‐Moeller, Nicolas Gaspard, Elizabeth E. Gerard, Giada Giovannini, Teneille Gofton, Margaret T. Gopaul, Marissa Kellogg, Stefano Meletti, Lorenzo Muccioli, Elena Pasini, Olga Taraschenko, Nathan Torcida, Mark S. Wainwright, Ji Yeoun Yoo, Nora Wong, Dominique Bonnefont‐Rousselot, Sophie Demeret, Lawrence J. Hirsch, Vincent Navarro +34 morewiley +1 more sourceDisease–Drug–Drug Interaction of Imatinib in COVID‐19 ARDS: A Pooled Population Pharmacokinetic Analysis
CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 583-595, March 2025.ABSTRACT
Prior pharmacokinetic (PK) analysis revealed that increased alpha‐1‐acid glycoprotein (AAG) levels are associated with decreased imatinib unbound fraction in coronavirus disease 2019 (COVID‐19) patients. This study aimed to investigate the PK of total and unbound concentrations of imatinib and the metabolite N‐desmethyl imatinib in ...Medhat M. Said, Job R. Schippers, Leila Atmowihardjo, Yingxue Li, Mick S. van der Plas, Harm J. Bogaard, Lieuwe D. J. Bos, Ron A. A. Mathôt, Jurjan Aman, Eleonora L. Swart, Imke H. Bartelink +10 morewiley +1 more sourceThe clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation
, 2016 Background: Juvenile idiopathic arthritis (JIA) is characterised by joint pain, swelling and limitation of movement caused by inflammation. Subsequent joint damage can lead to disability and growth restriction.Abbvie, Albarouni, All Wales Medicines Strategy Group, All Wales Medicines Strategy Group, All Wales Medicines Strategy Group, All Wales Medicines Strategy Group, Angeles-Han, Arthritis Care, Arthritis Care, Arthritis Care, Arthritis Care, Arthritis Research UK, Baildam, Baildam, Barton, Baszis, Bechtold, Berard, Bertilsson, Briggs, Briggs, Bristol-Myers Squibb, British Society for Paediatric and Adolescent Rheumatology, British Society for Paediatric and Adolescent Rheumatology, Brodszky, Brunner, Brunner, Brunner, Brunner, Brunner, Bruns, Bucher, Burgos-Vargas, Burgos-Vargas, Burgos-Vargas, Burgos-Vargas, Burgos-Vargas, Burgos-Vargas, Canadian Agency for Drugs and Technologies in Health, Chang, Chen, Connock, Consolaro, Consolaro, Consolaro, Consolaro, Cordero-Coma, Costa, Cummins, Cummins, Curtis, Dakin, De Benedetti, De Benedetti, Department of Health, Dias, Diaz-Llopis, Donegan, Drummond, Duffy, European Medicines Agency, European Medicines Agency, European Medicines Agency, European Medicines Agency, Feeny, Foeldvari, Gani, Garcia-De-Vicuna, Geikowski, Giannini, Glenny, Haapasaari, Heiligenhaus, Hendry, Higgins, Higgins, Horizon Scanning Centre, Horneff, Horneff, Imagawa, Joint Formulary Committee, Kearsley-Fleet, Kearsley-Fleet, Kemper, Khan, Kingsbury, Klein, Kuhlthau, Lloyd Jones, Lovell, Lovell, Lovell, Lovell, Lovell, Lovell, Lovell, Lovell, Luca, Luca, Lundkvist, Magli, Malottki, Martin, McErlane, McErlane, Mills, Minden, Minden, Monthly Index of Medical Specialties, Moorthy, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Rheumatoid Arthritis Society, National Rheumatoid Arthritis Society (NRAS), NHS England Clinical Reference Group for Paediatric Medicine, NHS England Specialised Services Clinical Reference Group for Specialised Ophthalmology, Nikolakopoulou, Office for National Statistics, Otten, Otten, Packham, Paediatric Formulary Committee, Parsons, Pennington, Petty, Pfizer Ltd, Philips, Prakken, Prince, Prince, Prince, Prince, Ramanan, Ravelli, Ravelli, Reeves, Riemsma, Rigante, Roche, Ruperto, Ruperto, Ruperto, Ruperto, Ruperto, Ruperto, Ruperto, Simonini, Simonini, Simpson, Simpson, Simpson, Smith, Sonnenberg, Stagi, Stevenson, Thierry, Thomson, Thornton, Tong, Tse, Tynjala, Ungar, Ungar, Vidqvist, Wallace, Wallace, Wallace, Yagudina, Zannin, Zeng +171 morecore +1 more sourceMesenchymal stromal cell therapy for rheumatoid arthritis: Long‐term efficacy, safety, and mechanistic insights
Rheumatology &Autoimmunity, EarlyView.Graphical abstract summarizing the multifactorial pathogenesis of rheumatoid arthritis (RA) and the therapeutic potential of mesenchymal stromal cell (MSC) therapy. MSCs provide promising benefits through their immunomodulatory properties, low immunogenicity, ability to promote tissue repair, and multi‐lineage differentiation, presenting a potential ...Yingjia Chen, Ruiyu Gao, Xing Guo, Genhong Yao, Xiaojun Tang, Yile E. Liu, Lingyun Sun +6 morewiley +1 more sourceSphinganine‐phosphate prevents influenza infection via promoting CD8+ T cells proliferation and activation
VIEW, EarlyView.This study established clinical cohorts of respiratory viral infections and identified sphinganine‐phosphate (SA) as a metabolite significantly upregulated post‐infection through metabolomic analysis. In vitro and in vivo experiments demonstrated that SA promotes the generation of effector CD8+ T cells via the SOCS1/JAK1/STAT1 pathway, which ...Zhongwen Hu, Guiling Yan, Junhong Li, Yuan Yuan, Hong Zhang, Yuchao Zhong, Yuanyuan Peng, Wenjia Zhang, Xiaoyan Su, Changchun Niu, Yang Luo +10 morewiley +1 more sourceCardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment [PDF]
, 2017 Risk of cardiovascular (CV) disease is increased among RA patients. High inflammatory burden associated with RA appears to be a key driver of the increased cardiovascular risk. Inflammation is linked with accelerated atherosclerosis and associated with a Choy, Ernest, Ganeshalingam, Kandeepan, Nurmohamed, Michael, Semb, Anne Grete, Szekanecz, Zoltán +4 morecore
